Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Use of amphotericin B lipid complex in aspergillus infections of the lung: efficacy and safety Source: Eur Respir J 2001; 18: Suppl. 33, 304s Year: 2001
Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA Source: Eur Respir J 2012; 39: 1261-1263 Year: 2012
Weekly nebulisation of liposomal amphotericin B for the treatment of endobronchial aspergillus fumigatus infection in cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 213s Year: 2004
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Development of in-vitro models for aerosolized surfactant therapy to support customization of a novel nebulizer system based on eflow technology Source: Annual Congress 2009 - Respiratory disorders of the newborn Year: 2009
Intrapulmonal deposition of two different tobramycin formulations Source: Eur Respir J 2005; 26: Suppl. 49, 729s Year: 2005
A preliminary assessment of the stability of 5-CF containing liposomes following aerosolisation with TouchSprayÔ technology and a commercial jet nebuliser Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003
Effect of breath-actuated mechanism on the emitted particle characteristics and lung deposition of a fixed combination drug Source: International Congress 2017 – Inhalers and their use Year: 2017
Antimicrobial properties of aerosolized liposomal cyclosporine (L-CsA) in lung transplantation patients – An in vitro study Source: Annual Congress 2010 - Pre-operative evaluation and post-operative problems after lung transplantation Year: 2010
A human lung reperfusion model for monitoring the initial pulmonary absorption of drugs from aerosol devices Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Evaluation of delivered dose and treatment time of several mesh nebulizers under in vitro simulated use Source: International Congress 2017 – Inhalers and their use Year: 2017
In vitro comparison of emitted dose with 2 types of nebulizers during non invasive ventilation Source: Annual Congress 2012 - New insights in the physical assessment and therapy of respiratory patients Year: 2012
In-vitro comparison of tobramycin nebulised using two different nebuliser systems Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
In vitro fine particle dose of drug formulation used in asthma & COPD Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
Inhaled solid lipid nanoparticles as a new tool for drug delivery in the lung Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Nebulised lipid–polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells Source: ERJ Open Res, 5 (2) 00161-2018; 10.1183/23120541.00161-2018 Year: 2019
A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
In-vitro deposition study of a levofloxacin (LEV) solution into a novel human nasal cast model by the PARI VibrENTÔSource: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Relative lung deposition of tobramycin from a MicroAir nebuliser Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006